Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared an article by R.S. Matulewicz, et al. on LinkedIn:
“Postchemotherapy Retroperitoneal Lymph Node Dissection.
This study challenges the routine 1 cm residual mass cut-off in clinical practice, demonstrating that even with residual masses <1 cm, viable tumor (2%) and teratoma (22%) are detected.
Is it time to reconsider the RPLND criteria?”
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ cell tumors.
Authors: R.S. Matulewicz, et al.
